Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation

2021 ◽  
Author(s):  
Lærke Marie Nelson ◽  
Thomas Emil Christensen ◽  
Kasper Rossing ◽  
Philip Hasbak ◽  
Finn Gustafsson
Keyword(s):  
Positron Emission Tomography ◽  
Heart Transplantation ◽  
Prognostic Value ◽  
Emission Tomography ◽  
Flow Reserve ◽  
Positron Emission ◽  
Long Term Follow Up ◽  
Myocardial Flow

Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor

2010 ◽  
Vol 20 (5) ◽  
pp. 694-697
Author(s):  
Margherita Giorgini ◽  
Claudia Marchetti ◽  
Violante Di Donato ◽  
Jacopo Tesei ◽  
Natalina Manci ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Primary Treatment ◽  
Emission Tomography ◽  
Borderline Ovarian Tumor ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Long Term Follow Up ◽  
Fluorodeoxyglucose Positron Emission

Most borderline ovarian tumors (BOT) occur in young women and exhibit a low malignant behavior. Nevertheless, an accurate long-term follow-up is required because, frequently, recurrence arises after many years from primary treatment, especially in patients affected by BOT with invasive peritoneal implants, which have a worse prognosis. We report the case of a pelvic recurrence of serous BOT firstly suspected by physical examination but misdiagnosed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography and identified only by magnetic resonance imaging, 7 years after primary treatment. We also reviewed the literature concerning the role of 18F-fluorodeoxyglucose positron emission tomography in the management and follow-up of BOT.

scholarly journals Prognostic value of regional myocardial flow reserve derived from 13N-ammonia positron emission tomography in patients with suspected coronary artery disease

2021 ◽  
Author(s):  
Elia von Felten ◽  
Dominik C. Benz ◽  
Georgios Benetos ◽  
Jessica Baehler ◽  
Dimitri Patriki ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Prognostic Value ◽  
Suspected Coronary Artery Disease ◽  
Emission Tomography ◽  
Flow Reserve ◽  
Positron Emission ◽  
Artery Disease ◽  
Myocardial Flow ◽  
Group 1

Abstract Purpose To assess the prognostic value of regional quantitative myocardial flow measures as assessed by 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI) in patients with suspected coronary artery disease (CAD). Methods We retrospectively included 150 consecutive patients with suspected CAD who underwent clinically indicated 13 N-ammonia PET-MPI and who did not undergo revascularization within 90 days of PET-MPI. The presence or absence of a decreased global myocardial flow reserve (i.e., MFR < 2) as well as decreased regional MFR (i.e., ≥ 2 adjacent segments with MFR < 2) was recorded, and patients were classified as having preserved global and regional MFR (MFR group 1), preserved global but decreased regional MFR (MFR group 2), or decreased global and regional MFR (MFR group 3). We obtained follow-up regarding major adverse cardiac events (MACE, i.e., a combined endpoint including all-cause death, non-fatal myocardial infarction, and late revascularization) and all-cause death. Results Over a median follow-up of 50 months (IQR 38–103), 30 events occurred in 29 patients. Kaplan–Meier analysis showed significantly reduced event-free and overall survival in MFR groups 2 and 3 compared to MFR group 1 (log-rank: p = 0.015 and p = 0.013). In a multivariable Cox regression analysis, decreased regional MFR was an independent predictor for MACE (adjusted HR 3.44, 95% CI 1.17–10.11, p = 0.024) and all-cause death (adjusted HR 4.72, 95% CI 1.07–20.7, p = 0.04). Conclusions A decreased regional MFR as assessed by 13 N-ammonia PET-MPI confers prognostic value by identifying patients at increased risk for future adverse cardiac outcomes and all-cause death.

Association Between Impaired Myocardial Flow Reserve on 82 Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease

2021 ◽  
Vol 14 (9) ◽  
Author(s):  
Attila Feher ◽  
Nabil E. Boutagy ◽  
Evangelos K. Oikonomou ◽  
Yi-Hwa Liu ◽  
Edward J. Miller ◽  
...  
Keyword(s):  
Heart Failure ◽  
Positron Emission Tomography ◽  
Adverse Events ◽  
Cox Regression ◽  
Emission Tomography ◽  
Autoimmune Rheumatic Disease ◽  
Flow Reserve ◽  
Positron Emission ◽  
Perfusion Defects ◽  
Myocardial Flow

Background: Coronary microvascular dysfunction has been described in patients with autoimmune rheumatic disease (ARD). However, it is unknown whether positron emission tomography (PET)-derived myocardial flow reserve (MFR) can predict adverse events in this population. Methods: Patients with ARD without coronary artery disease who underwent dynamic rest-stress 82 Rubidium PET were retrospectively studied and compared with patients without ARD matched for age, sex, and comorbidities. The association between MFR and a composite end point of mortality or myocardial infarction or heart failure admission was evaluated with time to event and Cox-regression analyses. Results: In 101 patients with ARD (88% female, age: 62±10 years), when compared with matched patients without ARD (n=101), global MFR was significantly reduced (median: 1.68 [interquartile range: 1.34–2.05] versus 1.86 [interquartile range: 1.58–2.28]) and reduced MFR (<1.5) was more frequent (40% versus 22%). MFR did not differ among subtypes of ARDs. In survival analysis, patients with ARD and low MFR (MFR<1.5) had decreased event-free survival for the combined end point, when compared with patients with and without ARD and normal MFR (MFR>1.5) and when compared with patients without ARD and low MFR, after adjustment for the nonlaboratory-based Framingham risk score, rest left ventricular ejection fraction, severe coronary calcification, and the presence of medium/large perfusion defects. In Cox-regression analysis, ARD diagnosis and reduced MFR were both independent predictors of adverse events along with congestive heart failure diagnosis and presence of medium/large stress perfusion defects on PET. Further analysis with inclusion of an interaction term between ARD and impaired MFR revealed no significant interaction effects between ARD and impaired MFR. Conclusions: In our retrospective cohort analysis, patients with ARD had significantly reduced PET MFR compared with age-, sex-, and comorbidity-matched patients without ARD. Reduced PET MFR and ARD diagnosis were both independent predictors of adverse outcomes.

Sign in / Sign up

Export Citation Format

Share Document